Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trencam-3,2-Hopo is a synthetic small molecule belonging to the class of salicylamides and is structurally related to hydroxypyridinone (HOPO) chelators. It acts as a multidentate chelating agent capable of binding metal ions such as iron and various radiometals. The compound has been studied primarily for its ability to form stable complexes with metals for use in targeted imaging and potential therapeutic applications, particularly in the context of radiopharmaceuticals for positron emission tomography (PET). Trencam-3,2-Hopo derivatives have been evaluated as bifunctional chelators that can be conjugated to targeting moieties (such as PSMA ligands) for selective delivery of radiometals like gallium-68 or titanium-45 to tumors expressing specific antigens[1][5][8]. Its mechanism involves strong coordination with metal ions via its HOPO groups; this property underlies its utility both in diagnostic imaging and potentially in decorporation therapy or MRI contrast enhancement[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Trencam-3,2-Hopo.